nmsg

News

21 Ignyta announces phase 1 clinical trial data for Entrectinib Jun 1, 2015
22 “Science Corner” di Nerviano, ospite il dr Siena dell’Ospedale Niguarda: “Tra le due strutture di Ricerca e Cura una collaborazione produttiva, all’avanguardia a livello mondiale, che ha portato contributi concreti all’oncologia di precisione.” May 8, 2015
23 Nerviano Medical Sciences: new personalized treatments active on acute myeloid leukemia, gastrointestinal and female tumors, with innovative opportunities of dna repair processes Apr 21, 2015
24 SOT 2015: presented by Accelera and StemGen new data on treatment of glioblastoma, the most common brain tumor. Mar 27, 2015
25 Four presentations from Nerviano Medical Sciences at the 2015 AACR meeting Mar 18, 2015
26 Rector of the University of Milan visiting Nerviano Campus Jan 23, 2015
27 Tiziana Life Sciences licenses milciclib from Nerviano Medical Sciences Jan 20, 2015
28 Il Prof. Carlo Croce, Vice Presidente con delega alla direzione scientifica di Nerviano, ambasciatore della ricerca italiana sul cancro al Quirinale al cospetto del Presidente della Repubblica Nov 6, 2014
29 Nerviano Medical Sciences discloses novel molecules suitable for the generation of antibody drug conjugates at the World ADC, San Diego (USA) 2014 Nov 6, 2014
30 Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014 Oct 28, 2014

Page 3 of 4

To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.